At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 58 enrolled
Drug / intervention
TAK-925 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Study of TAK-925 to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of TAK-925 in Healthy Adult and Elderly Volunteers and Patients With Narcolepsy
In Brief
A Phase 1 clinical trial evaluating TAK-925 and Placebo for Healthy Participants and Patients With Narcolepsy. Completed, enrolled 58 participants across 3 sites.
Detailed Summary
The purpose of this study is to investigate safety, tolerability, and pharmacokinetics of TAK-925 when a single dose of TAK-925 is administered to healthy adult participants, healthy elderly participants and patients with type 1 narcolepsy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesJapan
Collaborators--
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
Enrollment StartNov 2017
First PostedNov 2017
Primary CompletionSep 2018
TodayJul 2026
First PostedNov 6, 2017
Enrollment StartNov 4, 2017
Primary CompletionSep 4, 2018
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 8.7 years ago
Interventions
TAK-925drug
TAK-925 Intravenous Infusion
Placebodrug
TAK-925 Placebo Intravenous Infusion